Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

Inspired by advances in cancer therapy, a team at the Buck Institute has engineered immune cells equipped with specialized targeting devices called chimeric antigen receptors (CARs) that can ...

Protection through 2039, ensuring long-term commercial exclusivity. NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a ...

Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and ...

May 2025 marked another key milestone for Reacta Healthcare, as the first production run of pharmaceutical grade milk and egg ...

To assess T-cell-induced morphological changes, each organoid was segmented in the transmitted light (TL) channel using a ...

Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based ...

Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized ...

AstraZeneca Plc said a handful of patients with lupus went into remission after getting an experimental treatment, as the UK ...

Fintel reports that on June 10, 2025, B of A Securities downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) from ...